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enhance inflammation 2	
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ABSTRACT  21	
The role of cytokines and chemokines in anti-viral defense has been demonstrated, but 22	
their relative contribution to protective anti-viral responses in vivo is not fully 23	
understood. Cytokine response modifier D (CrmD) is a secreted receptor for TNF and 24	
lymphotoxin containing the smallpox virus-encoded chemokine receptor (SECRET) 25	
domain and is expressed by ectromelia virus, the causative agent of the smallpox-like 26	
disease mousepox. Here we show that CrmD is an essential virulence factor that 27	
controls natural killer cell activation and allows progression of fatal mousepox, and 28	
demonstrates that both SECRET and TNF binding domains are required for full CrmD 29	
activity. Vaccination with recombinant CrmD protects animals from lethal mousepox. 30	
These results indicate that a specific set of chemokines enhance the inflammatory and 31	
protective anti-viral responses mediated by TNF and lymphotoxin, and illustrate how 32	
viruses optimize anti-TNF strategies with addition of a chemokine binding domain as 33	
soluble decoy receptors.  34	
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INTRODUCTION 35	
 36	
A unique immune evasion mechanism employed by poxviruses and herpesviruses is the 37	
production of soluble binding proteins or secreted versions of host receptors that 38	
neutralize cytokines1-4. The poxvirus homologues of host tumour necrosis factor TNF 39	
(TNF) receptors (vTNFRs) block the pro-inflammatory activity of some TNF 40	
superfamily (TNFSF) ligands. Five vTNFRs have been described in poxviruses, a viral 41	
homologue of host TNFSF receptor CD30 and four TNF inhibitors named cytokine 42	
response modifier B (CrmB), CrmC, CrmD and CrmE. vTNFRs are differently 43	
expressed among viral species and show distinct binding and inhibitory properties5-13. 44	
While CrmE and CrmC are specific TNF inhibitors, CrmD and CrmB block TNF and 45	
lymphotoxin a (LTa). Furthermore, we have recently described that vTNFRs can 46	
inhibit membrane TNF and that CrmD and CrmB neutralize another TNFSF ligand, 47	
LTb14,15. In addition to the cysteine-rich domains (CRDs), characteristic of the ligand 48	
binding region of cellular TNFRs, CrmB and CrmD have a C-terminal domain 49	
unrelated to host proteins that binds chemokines and was named SECRET (for smallpox 50	
virus-encoded chemokine receptor) domain16. The crystal structure of the CrmD 51	
SECRET domain showed a beta-sandwich fold similar to that of the viral chemokine 52	
binding proteins (vCKBPs) 35-kDa and A41, but a different chemokine interaction 53	
region may confer its distinct narrower binding specificity17-19. Such variety of activities 54	
may provide poxviruses the ability to differentially block chemokines involved in 55	
distinct anti-viral responses, to inhibit chemokines at different stages of infection in the 56	
host or to simultaneously inhibit chemokines and TNF. Interestingly, the beta-sandwich 57	
fold of vCKBPs has also been observed in other unrelated poxviral proteins including 58	
CPXV203, a major histocompatibility complex I binding protein encoded by cowpox 59	
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virus (CPXV), and GIF, the granulocyte-macrophage colony-stimulating factor and 60	
interleukin 2 inhibitor of the parapox Orf virus 4,20. To reflect such diverse range of 61	
immunomodulatory activities this folding has been named as poxvirus immune evasion 62	
domain4,20. 63	
ECTV is a mouse-specific orthopoxvirus21,22 genetically related to vaccinia virus 64	
(VACV), variola virus (VARV) (the causative agent of human smallpox) and 65	
monkeypox virus (MPXV)23,24, a human pathogen whose incidence is increasing due to 66	
the cessation of mass smallpox vaccination in Africa25,26. Susceptible strains of mice 67	
infected with ECTV develop mousepox, a severe disease that constitutes a good model 68	
for smallpox. ECTV infection of susceptible mouse strains via the s.c. route has been 69	
exploited as a model of generalized virus infections, genetic resistance to disease, and 70	
viral immunology21,22,27. In ECTV, CrmD is the only secreted TNFR. Similarly, both 71	
VARV and MPXV express a single vTNFR with similar characteristics, CrmB. By 72	
contrast, CPXV expresses four distinct vTNFRs13. In addition, ECTV and other 73	
poxviruses encode intracellular proteins that inhibit TNF-induced signalling, 74	
underscoring the importance of TNF in antiviral reponses18,28.  75	
However, our knowledge of the role of TNF and LT in the control of poxviral infections 76	
in vivo is limited. Knockout mice lacking both TNFR1 and TNFR2 showed a slightly 77	
increased susceptibility to ECTV and elevated viral replication, with 60% of the 78	
infected animals succumbing to mousepox while all WT mice resisted infection 29. A 79	
direct antiviral activity of TNF has been proposed using a recombinant VACV 80	
expressing TNF30. This direct effect was substantiated in TNF-deficient mice infected 81	
with VACV, which showed a modest (two-fold) reduction in LD50 as compared to WT 82	
mice, that was accompanied by an increased virus load but not by a diminished T cell 83	
response31. Although resistance to mousepox was associated with Th1-like cytokine 84	
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expression, including TNF, blockade of TNF using monoclonal antibodies did not affect 85	
the generation of NK cell and CTL responses, virus clearance or resistance to ECTV 86	
infection32 and treatment with TNF did only reduce the mortality rate from 100% to 87	
70% in susceptible BALB/c mice33. VACV-infected TNFR2-deficient C57BL6 mice 88	
produced higher viral titers in spleens and livers and reduced numbers of inflammatory 89	
cell foci in the liver, as compared to WT mice34. 90	
A contribution of vTNFRs to pathogenesis was initially shown with a CPXV lacking 91	
CrmB, but expressing other vTNFRs, which displayed an increased LD50 in infected 92	
mice after intracranial inoculation, a route of infection not natural for poxviruses35. 93	
Inactivation of a CrmB homologue (M-T2) from myxoma virus reduced clinical signs 94	
of illnesss in infeced rabbits36. However, the reported attenuation in the initial studies 95	
cannot be formally atributed solely to the absence of the vTNFR since the selection of 96	
inadvertent mutations elsewhere in the viral genome was not controlled with the 97	
construction of revertant viruses or by sequencing the complete viral genome. 98	
Additional studies with the VACV vaccine strain USSR showed that deletion of CrmC 99	
or CrmE caused no effect in virulence or a very mild attenuation not affecting mortality, 100	
respectively, after i.n. infection of mice37. Recombinant VACV strain Western Reserve 101	
expressing CrmC, CrmB or CrmE displayed increased virulence less than 10-fold in an 102	
i.n. mouse model, but high virus doses were required to cause disease because the 103	
recombinant viruses were deficient in the thymidine kinase gene37,38. Definitive studies 104	
addressing the role of vTNFRs in viral pathogenesis using virulent poxviruses in their 105	
natural host are lacking. 106	
Here we show that CrmD is an essential virulence factor as deletion of CrmD from 107	
ECTV resulted in a dramatic attenuation phenotype, generating an avirulent virus that 108	
induced strong NK cell and CD8 T cell responses but did not establish fatal mousepox. 109	
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This demonstrates a critical role of TNF and a reduced set of chemokines in anti-viral 110	
defense. Moreover, this unique model of virus infection in a natural host, together with 111	
the construction of mutant viruses, allowed us to dissect the relative contribution of 112	
TNF and chemokine activities in vivo. We report that expression of the anti-TNF (CRD 113	
domain) or anti-chemokine (SECRET domain) activities of CrmD are not sufficient on 114	
their own to confer full virulence to ECTV, suggesting that the function of some 115	
chemokines complement TNF in protection against viruses. Furthermore, immunization 116	
of mice with recombinant CrmD protected from a lethal ECTV challenge.  117	
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RESULTS 118	
 119	
ECTV CrmD is an essential virulence factor 120	
To address the role of CrmD in mousepox pathogenesis, we generated recombinant 121	
ECTVs in the Naval strain (Fig. 1a). An ECTV CrmD deletion mutant was obtained 122	
(ECTVΔCrmD) with both copies of the CrmD gene deleted. As a control for the 123	
selection of inadvertent mutations in other genes during the generation of 124	
ECTVΔCrmD, a revertant virus (ECTVRevCrmD) with both copies of the full length 125	
CrmD gene restored was constructed. To study the differential contribution of TNF- vs 126	
chemokine- inhibitory activities of CrmD, a virus expressing only the TNF binding 127	
domain of CrmD, composed of CRDs (ECTVRevCRD), was constructed. The complete 128	
genome sequence of ECTVRevCRD confirmed the correct incorporation of two copies 129	
of the truncated CrmD TNF binding domain and the absence of additional mutations. 130	
Replication of recombinant viruses was comparable to that of the parental ECTV (Fig. 131	
1d). As expected, ECTVΔCrmD-infected cell supernatants showed neither expression 132	
of CrmD protein nor TNF blocking activity, whereas infections with either parental or 133	
revertant viruses showed similar levels of CrmD and TNF inhibitory activity (Fig. 1b, 134	
c). ECTVRevCRD-infected cells expressed a truncated CrmD protein that inhibited 135	
TNF activity as efficiently as supernatants from ECTV- or ECTVRevCrmD-infected 136	
cells. As a control, all samples expressed similar amounts of the secreted 35-kDa 137	
vCKBP39 (Fig. 1b).  138	
Viral virulence was determined in susceptible BALB/c mice s.c. in the footpad (Table 139	
1). Only four out of 20 animals infected with 10 PFU of either parental or 140	
ECTVRevCrmD viruses survived the disease, with an estimated LD50 of less than 10 141	
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PFU. In contrast, ECTVΔCrmD was severely attenuated, as only one animal out of five 142	
died when 107 PFU were administered while all other mice survived. This difference of 143	
at least six orders of magnitude in LD50 of ECTVΔCrmD as compared to ECTV 144	
indicated that CrmD is an essential virulence factor in mousepox and that its deletion 145	
renders ECTV practically avirulent. Reintroduction of both copies of the full length 146	
CrmD into the genome of ECTVΔCrmD restored virulence, demonstrating an exclusive 147	
CrmD-mediated effect. Interestingly, the LD50 estimated for mice infected with 148	
ECTVRevCRD was around 105 PFU, showing attenuation of the virus lacking only the 149	
chemokine inhibitory domain as compared to parental and revertant ECTVRevCrmD 150	
viruses. This indicated that the SECRET domain was essential for pathogenesis. 151	
 152	
ECTV CrmD controls an inflammatory reaction in vivo 153	
Infected animals were monitored daily for weight loss, signs of illness and footpad 154	
swelling (Fig. 2). As shown for two viral doses (10 PFU and 1,000 PFU per animal), 155	
mice infected with ECTVΔCrmD suffered less severe weight loss and signs of illness as 156	
compared to mice infected with parental or revertant ECTVRevCrmD viruses. Weight 157	
of ECTVΔCrmD-infected mice did not drop below 95% of their initial value and mean 158	
scores peaked at around 1 in a scale ranging from 0 for a healthy individual to 4 for a 159	
severely diseased animal. ECTVΔCrmD-infected mice had fully recovered from disease 160	
by 16 d post-infection (dpi). Similarly, ECTVRevCRD-infected mice showed reduced 161	
weight loss and signs of illness, with surviving mice fully recovering (Fig. 2). In this 162	
case, the differences were more apparent at the lower doses. The thickness of the site of 163	
virus inoculation (footpad) was assessed as a measure of inflammatory response. In 164	
ECTV and ECTVRevCrmD-infected animals only a few individuals responded with 165	
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footpad swelling, starting at 10 dpi, when most of the mice had succumbed to infection. 166	
However, ECTVΔCrmD-infected mice showed a strong footpad swelling starting 2-3 167	
days earlier and peaking by 10-11 dpi at values higher than those observed with parental 168	
virus (Fig. 2). Thus, CrmD efficiently controls footpad swelling, consistent with its 169	
proposed immunomodulatory role (Fig. 3a, b).  170	
In mice infected with ECTVRevCRD, expressing the TNF but not the chemokine 171	
blocking activity of CrmD, footpad swelling was significantly delayed as compared to 172	
that observed in the absence of CrmD, showing that TNF activity in vivo is crucial for 173	
an inflammatory reaction. However, inflammation did still occur, which could reflect an 174	
incomplete blockade of TNF activity as well as the activity of other proinflammatory 175	
stimuli, such as the chemokines not blocked due to the absence of the SECRET domain 176	
in this virus. Haematoxilin and eosin (H&E) staining of sections of the footpad of 177	
ECTVΔCrmD-infected mice showed the presence of a large inflammatory infiltrate 178	
with edema in the dermis, which was not detected or much reduced in ECTV-infected 179	
mice (Fig. 3c, d). The infiltrate was composed mainly of lymphocytes (Fig. 3g) and 180	
macrophages with a few polymorphonuclear leukocytes. Immunostaining showed the 181	
presence of CD4+ T cells (10% CD3+; 12% CD4+) and some B cells (5%), but no 182	
CD8+ cells were detected. Sections were stained for expression of Inter Cellular 183	
Adhesion Molecule-1 (ICAM-1), an integrin ligand overexpressed on endothelial cells 184	
of the postcapillary venules in response to proinflammatory cytokines such as TNF 40. 185	
More than 50% of vessels in the footpads of ECTVΔCrmD-infected mice showed 186	
intense ICAM-1 staining, while only around 25% of vessels expressed ICAM-1 in 187	
ECTV- or ECTVRevCrmD-infected mice (Fig. 3e, f), indicating a role for CrmD in 188	
controlling inflammation through TNF inhibition. Our previous studies defined the 189	
binding specificity of CrmD for human chemokines16, and we have characterized here 190	
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the interaction of CrmD with mouse chemokines (Fig. 4). Consistent with the anti-191	
chemokine activity of CrmD, immunohistochemistry of footpad sections showed that 192	
approximately 30% of the infiltrating cells in ECTVΔCrmD-infected mice by 7 dpi 193	
expressed the CCR10 chemokine receptor (Fig. 3h) whereas no CCR10-expressing cells 194	
were observed in ECTV infections. The CrmD SECRET domain interacts with the 195	
mouse chemokines Ccl28 and Ccl27, the latter with higher affinity (Fig. 4), which are 196	
recognized by CCR10. This indicates that the SECRET domain may contribute to the 197	
inhibition of chemokine-directed cell migration in vivo. Consistently, a similar amount 198	
of CCR10-expressing cells was detected in the footpad infiltrate of ECTVRevCRD-199	
infected mice. 200	
 201	
 202	
Virus replication is restricted in the absence of ECTV CrmD 203	
The extent of viral replication and dissemination in the host in the absence of CrmD was 204	
analysed. Viral replication was apparently not hindered at the site of inoculation, as 205	
assessed by anti-virus and anti-CrmD staining of sections from footpads of infected 206	
mice at 7 dpi (Fig. 5c-h). This also showed that ECTV replicates in vivo in the absence 207	
of CrmD and the stability of the truncated CRD protein in vivo. Staining of sections 208	
from footpads of uninfected mice showed the specificity of the anti-virus and anti-209	
CrmD antibodies (Supplementary Fig. 1). As shown in Fig. 5a and b, by 3 dpi, all four 210	
viruses had reached both the spleen and liver, with no significant differences in the viral 211	
titers among them, suggesting that the absence of CrmD did not affect the capacity of 212	
the virus to spread to its secondary replication sites. However, both the parental and the 213	
revertant ECTVRevCrmD viruses reached high titers by 7 dpi in the spleen (Fig. 5a) 214	
	 11	
and liver (Fig. 5b), whereas ECTVΔCrmD titers were reduced by 2 and 4 log units in 215	
these organs, respectively. This shows that ECTV replication in spleen and liver is 216	
controlled by the host in the absence of CrmD. The expression of the TNF inhibitory 217	
domain of CrmD by ECTVRevCRD fully restored ECTV infectivity in spleen, but not 218	
in the liver, suggesting that the relative contribution of TNF activity for protection 219	
against virus replication in vivo might be organ-dependent. These results also suggest 220	
that chemokine inhibition by the SECRET domain may be especially important for 221	
virus replication in the liver. All mice infected with either ECTVΔCrmD or 222	
ECTVRevCRD survived the infection and virus was being cleared by 11 dpi (Fig. 5a, 223	
b). Limited virus replication in the absence of CrmD was accompanied by reduced 224	
necrosis of the infected organs (Fig. 5j, m, Table 2, Supplementary Fig. 2), which was 225	
also apparent in the liver in the case of ECTVRevCRD-infected mice (Fig. 5n and Table 226	
2). Additionally, an increased inflammation of the liver at 7 or 11 dpi was observed in 227	
the absence of CrmD (Fig. 5m and Table 2). Altogether, these results showed that in the 228	
absence of CrmD ECTV replication can be controlled by the host and suggest that 229	
reduced liver damage is the cause for survival of infected mice. 230	
 231	
 232	
ECTV requires inhibition of chemokines and TNF for virulence 233	
To further assess the role of the CrmD SECRET domain in mousepox pathogenesis, a 234	
recombinant virus was constructed in which CrmD was replaced by a CrmD variant 235	
bearing a point mutation (N77F) that lacks TNF binding and inhibitory activity while 236	
maintaining its chemokine inhibitory activity. Fig. 6 shows the binding and biological 237	
properties of the purified recombinant CrmD N77F mutant, demonstrating that it has 238	
lost the TNF inhibitory activity but retains the ability to inhibit chemokine-mediated 239	
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cell migration, with a similar potency as that shown by CrmD. The complete genome 240	
sequence of this virus, termed ECTVRevSECRET, confirmed the incorporation of two 241	
copies of the CrmD N77F mutant gene and that no other mutations that may influence 242	
virus virulence were present. ECTVRevSECRET replicated efficently in cell culture 243	
and expressrd the mutated protein to similar levels than the parental virus, considering 244	
the loading control of vCKBP (Fig. 7b). As expected, supernatants of 245	
ECTVRevSECRET-infected cells did not show TNF inhibitory activity (Fig. 7c). 246	
The virulence of ECTVRevSECRET was assessed in susceptible BALB/c mice infected 247	
s.c. in the footpad with virus doses ranging from 104 to 106 PFU per animal. With only 248	
one animal out of 5 succumbing to mousepox after infection with the highest dose 249	
tested (Fig. 7d, e), ECTVRevSECRET was nearly as severely attenuated as the 250	
ECTV∆CrmD mutant. ECTVRevCRD, expressing the TNF binding domain, was 251	
slightly more virulent than ECTVRevSECRET, expressing the chemokine binding 252	
activity. ECTVRevSECRET was able to replicate in vivo and to reach the spleen, but 253	
replicated to levels lower than ECTVRevCRD and ECTVRevCrmD (Fig. 7f). As shown 254	
before, infection with 106 PFU of ECTV∆CrmD produced a strong footpad swelling 255	
starting at 5 dpi, that was impaired by expression of CrmD (ECTVRevCrmD) or the 256	
TNF binding domain of CrmD (ECTVRevCRD) (Fig. 7e). Expression of the chemokine 257	
binding activity of CrmD by ECTVRevSECRET was also able to block this 258	
inflammatory reaction, albeit to a reduced degree (Fig. 7e). Altogether, these results 259	
showed that the SECRET domain chemokine inhibitory activity per se is not able to act 260	
as a virulence factor, suggesting that its role in pathogenesis is only apparent when the 261	
TNF inhibitory activity is also expressed by the virus.  262	
 263	
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Modulation of NK cell and CD8 T cell responses by CrmD  264	
It has been shown that upon footpad inoculation of ECTV, the NK cell response during 265	
the first 4 dpi in the draining popliteal LN (DPLN) and the T cell response at late stages 266	
(peak at 7 dpi) in the secondary organs are required to survive lethal mousepox 21,22. To 267	
understand the mechanisms by which ECTV CrmD allows viral replication and whether 268	
it impairs the immune response, we studied the early NK cell response and the late T 269	
cell response against the different recombinant viruses in the DPLN at 2 dpi and in the 270	
spleen at 7 dpi, respectively. 271	
The NK cell population (CD3-DX5+) of all the infected groups represented around 3% 272	
of the cells in the DPLN whereas it was less than 1% in the PBS-inoculated group (Fig. 273	
8a, c). Furhermore, no differences in the total number of NK cells present in the DPLN 274	
at 2 dpi were found among the different infected groups (Fig. 8b). This suggested that 275	
CrmD is not involved in controling the recruitment of NK cells to early virus replication 276	
sites. However, differences in the activation status of NK cell populations were found. 277	
In the PBS-inoculated group less than 2% of NK cells were activated, as assessed by 278	
granzyme B expression (Fig. 8d). Conversely, in mice infected with recombinant 279	
viruses lacking the TNF blocking ability, ECTV∆CrmD and ECTVRevSECRET, more 280	
than 20% of NK cells were activated. In contrast, viruses expressing the TNF binding 281	
domain, ECTVRevCRD and ECTVRevCrmD, significantly controlled NK cell 282	
activation, reducing by half the % of granzyme B+ NK cells (Fig. 8d).  These results 283	
suggested that the anti-TNF activity of CrmD impairs the early NK cell activation in 284	
response to ECTV infection.  285	
At 7 dpi, infection with the CrmD-expressing virus produced an almost complete 286	
elimination of CD8 T cells from the spleens (Fig. 8a, e). It is important to clarify that 287	
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although the representative dot blot in Fig. 8a (bottom panel) still shows a 1.9% of CD8 288	
T cells in the spleen of ECTVRevCrmD-infected mice, this was only slightly above the 289	
staining observed with the corresponding isotype control (1.3%). In addition, only 40% 290	
of the analyzed cells fell inside the lymphocyte gate in this group, whereas the analysis 291	
gate gathered more than 80% of the cells in all the other groups (Supplementary Fig. 3). 292	
These two factors explain the almost complete depletion of CD8 cells in mice infected 293	
with ECTVRevCrmD shown in Fig. 8e. This splenic lymphopenia has been observed 294	
previously in ECTV lethal infections41-43. In mice infected with either ECTV∆CrmD, 295	
ECTVRevCRD or ECTVRevSECRET, however, CD8 T cells were detectable and 296	
efficiently activated in response to infection (Fig. 8a, e and f). This showed that the 297	
presence of both the TNF and chemokine binding domains in the CrmD protein is 298	
necessary for the inhibition and elimination of CD8 T cells in the spleen, and for full 299	
virulence of ECTV. 300	
 301	
 302	
Immunization with ECTV CrmD protects from fatal mousepox 303	
As ECTV infection was severely attenuated in the absence of ECTV CrmD, we 304	
hypothesized that a blockade of ECTV CrmD protein may prevent the development of 305	
mousepox. To test this, we immunized susceptible mice with purified recombinant 306	
ECTV CrmD protein and challenged them with a lethal dose (100-fold LD50) of ECTV, 307	
to test the induction of an efficient protective response. Sera from CrmD-immunized 308	
mice (14 out of 15 mice), but not from control mice, neutralized the ability of CrmD to 309	
inhibit TNF activity in a cytotoxicity assay (Fig. 9a, 2 µl dose) causing <50% cell 310	
viability. Addition of a lower amount of sera in the TNF biological assay identified a 311	
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weaker CrmD neutralization activity in 3 of the 5 mice that succumbed to infection after 312	
CrmD immunization (Fig. 9a, 1 µl dose). After ECTV inoculation, mice previously 313	
immunized with CrmD developed mousepox signs and suffered weigth loss to a similar 314	
degree as those injected with PBS (Fig. 9b, c). However, the immunized mice showed 315	
very early and acute footpad swelling in response to infection (Fig. 9d), reminiscent of 316	
that observed in ECTVΔCrmD-infected mice and suggesting that ECTV CrmD activity 317	
produced by WT ECTV was neutralized in these animals. Moreover, 67% of the CrmD 318	
immunized mice survived infection and had fully recovered by 30 dpi, while all the PBS 319	
injected mice had died by 10 dpi (Fig. 9e). 320	
 321	
 322	
DISCUSSION 323	
The results presented here show that ECTV CrmD is an essential factor for mousepox 324	
virulence and that both its TNF and chemokine inhibitory activities contribute to its 325	
immunomodulatory role. ECTV replication in secondary replication organs, spleen and 326	
liver, was impaired in the absence of CrmD. The most probable cause of death during 327	
mousepox is liver failure due to extensive viral replication32. Therefore, reduced viral 328	
replication and hence necrosis in this organ may account for survival of mice infected 329	
with ECTV lacking either the full length CrmD, or the anti-TNF or anti-chemokine 330	
activities of the protein. Additionally, expression of CrmD in the spleen and liver will 331	
block anti-viral responses in these organs, consistent with an increased inflammatory 332	
response in the liver of ECTVΔCrmD- and ECTVRevCRD-infected mice.  333	
Deletion of the CrmD gene from ECTV results in one of the most profound effects on 334	
virulence described in poxviruses17,18. Previous reports have shown that inactivation of 335	
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other vTNFRs secreted by VACV, CPXV and myxoma virus causes limited viral 336	
attenuation, and some reports are not conclusive35-37. Similarly, inactivation of vCKBPs, 337	
35-kDa and A41 proteins, from poxvirus genomes causes increased leukocyte 338	
recruitment to sites of infection without major effects on disease progression or 339	
mortality, or a slight attenuation as a result of reduced inflammatory pathology17,18. 340	
Interesting, deletion of the ECTV type I IFN binding protein, which targets a different 341	
cytokine, rendered the virus avirulent to a degree similar to that we observed after 342	
CrmD deletion44 . This suggests a possible link between the type I IFN and the 343	
TNF/LT/chemokine anti-viral host responses, as the link described for the type I IFN 344	
and nuclear factor kappa B pathways45. Increased LT signalling in the absence of CrmD 345	
could contribute to the induction of the IFN response, as described for murine 346	
cytomegalovirus46, restricting virus replication through increased type I IFN signalling 347	
to immune cells or direct effects on infected cells. In accordance with this, TNF and 348	
IFN may act synergistically in anti-viral defense47. Also, a role of the LT network in 349	
controlling the type I IFN response has been proposed48.  350	
Previous data suggested a role for TNF-induced signalling in mousepox pathogenesis, 351	
as transgenic resistant mice lacking functional TNFR1 and TNFR2 became susceptible 352	
to ECTV29. Consistently, treatment of susceptible BALB/c mice with murine TNF 353	
hindered ECTV replication and mortality to some extent33. However, TNF had a 354	
relatively minor role during ECTV or related poxvirus infections in terms of impact on 355	
LD50. Strikingly, the lack of the secreted TNF binding protein CrmD has a profound 356	
effect, reducing virulence almost completely. While specific experimental setups may 357	
account for these differences, they indicate a role of CrmD beyond inhibition of soluble 358	
TNF, which may include inhibition of LTa, LTb or chemokines. In addition, we have 359	
recently demonstrated that CrmD and other vTNFRs interact with membrane TNF and 360	
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inhibit its cytotoxic activity14. Further, CrmD may trigger reverse signaling in 361	
membrane TNF-bearing cells, as shown for viral CD307, and this may influence the 362	
anti-viral response.  363	
This CrmD-membrane TNF interaction might also explain the impaired activation of 364	
NK cells in the DPLN of mice infected with ECTVRevCrmD and ECTVRevCRD. NK 365	
cells are required at early stages to curb ECTV dissemination from the lymph nodes to 366	
the spleen and liver and ultimatelly, to survive to fatal mousepox41,49. Despite 367	
historically considered effector cells of the innate immunity, NK cell responses are 368	
greatly modulated by dendritic cells (DC)50,51, being more efficient when both cells are 369	
in direct contact	 50,51, and this is important for defense against other viral infection52. 370	
Accordingly, DC-depleted C57BL/6 mice are susceptible to ECTV53. The DC-NK 371	
crosstalk is mediated in mouse and human by the engagement of DC membrane TNF, 372	
but not soluble TNF, with NK TNFR254,55. Therefore, CrmD or the truncated TNF 373	
binding domain may be blocking the membrane TNF-TNFR2 interaction hindering an 374	
efficient DC-NK cell crosstalk. A weak NK cell activity might explain the high viral 375	
titers of ECTV and ECTVRevCRD detected later in the spleen, whereas the 376	
dissemination of ECTVRevSECRET and the CrmD deletion mutant is curbed by a 377	
potent early NK cell response. After 4 dpi NK cells are no longer required for resistance 378	
to ECTV challenge and the T cell response takes over41. At day 7 in the spleen, we 379	
observed a depletion of CD8 lymphocytes in mice infected with ECTV expressing 380	
CrmD, however, an efficient CD8 response was mounted against all the other viruses 381	
tested here. Of note, this CD8 cell depletion did not correlate with viral loads in the 382	
spleen since ECTVRevCRD, which reaches equally high viral titers, did not cause 383	
lymphopenia. This result suggests that both CrmD immunomodulatory activities, anti-384	
TNF and anti-chemokines, are required for complete control of the T cell response in 385	
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the spleen. Consistently, the SECRET domain binds Cxcl11, one of the ligands of the 386	
chemokine receptor CXCR3 that enhances the ability of CD8 T cells to locate VACV-387	
infected cells and to exert anti-viral effector functions56. In agreement with a role of 388	
both TNF and chemokines in T cell responses, neutralization with anti-TNF antibodies 389	
does not affect the splenic late CTL response against ECTV in C57BL/6 mice32. 390	
However, this might be an indirect effect since splenic lymphopenia has also been 391	
observed in other ECTV lethal infections where the host ability to mount an efficient 392	
TNF and chemokine response is intact41,42. 393	
Here we show that ECTV CrmD efficiently inhibits the establishment of a 394	
proinflammatory state at the site of virus inoculation, as evidenced by the increased 395	
ICAM-1 expression observed in its absence. The ability of CrmD to block TNF and LT 396	
activity, cytokines that induce the expression of ICAM-1 on endothelial cells, could 397	
account for this15,16. In the absence of CrmD, an increased inflammatory infiltrate was 398	
observed both in the footpad and in the liver, consistent with the chemokine inhibitory 399	
function of its SECRET domain. More specifically, an important fraction of the footpad 400	
infiltrate was composed of cells bearing the chemokine receptor CCR10, which 401	
supports migration of lymphocytes towards Ccl28 and Ccl27. Both chemokines are 402	
bound with high affinity by CrmD and expressed by skin keratinocytes in response to 403	
TNF and other proinflammatory stimuli16,57. Indeed, Ccl27 is important in T-cell 404	
mediated skin inflammation in vivo58. Thus, the potent anti-inflammatory activity of 405	
CrmD may be due to its ability to inhibit either TNF/LT as well as a set of chemokines. 406	
Consistent with this, VARV CrmB, with properties similar to CrmD, blocks cell 407	
migration induced after epicutaneous application of murine TNF59. 408	
The infection of mice with ECTVRevCRD or ECTVRevSECRET expressing the anti-409	
TNF/LT or anti-chemokine activity of CrmD, respectively, allowed us to address the 410	
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contribution of TNF/LT vs. chemokines to inflammatory and protective responses in 411	
vivo. Interestingly, ECTVRevCRD was not able to efficiently control the inflammatory 412	
infiltrate observed in ECTVΔCrmD-infected mice, in spite of the well-documented and 413	
potent pro-inflammatory function of TNF. This suggested that the activity of the mouse 414	
chemokines targeted by the SECRET domain (Ccl24, Ccl25, Ccl27, Cxcl11, Cxcl12β, 415	
Cxcl13 and Cxcl14) was sufficient to control cell migration and to trigger inflammation 416	
when TNF was neutralized by the truncated CrmD protein. The delay in the appearance 417	
of the inflammatory infiltrate in ECTVRevCRD-infected mice as compared to that 418	
observed with ECTVΔCrmD, probably reflects TNF blockade at the inoculation site 419	
and suggests the involvement of TNF in triggering the initial response in vivo. It is 420	
important to note that the infiltrating cells are probably contributing to an increased 421	
expression of cytokines, and thus chemokine blockade by the CrmD SECRET domain 422	
expressed in ECTVRevSECRET infections may impair localized TNF expression. 423	
Limited recruitment of cytokine producing cells into the sites of infection may be a 424	
general principle in host-pathogen interactions and help pathogens escape the host 425	
response, as shown in a Leishmamia major mouse model of dermal infection60 and in 426	
Listeria monocytogenes-infected mice, where Ccl2-induced recruitment of TNF and 427	
iNOS producing cells to the spleen mediates an effective innate immune response61. 428	
The reasons for the dramatic attenuation phenotype of the CrmD mutant could be 429	
related to the nature of the chemokines targeted and/or the inhibitory mechanism. The 430	
CrmD SECRET domain is different from the 35-kDa vCKBP in the specific set of 431	
chemokines blocked17,18. The VACV A41 protein and its ECTV Naval orthologue E163 432	
bind a number of chemokines including those recognized by the SECRET domain, but 433	
they do not block chemokine interaction with its receptor and is rather proposed to 434	
dissipate chemokine chemotactic gradients in vivo by targeting the glycosaminoglycan 435	
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binding site of chemokines17,18. Thus the 35-kDa vCKBP and A41 ECTV orthologues 436	
are probably involved in controlling different aspects of the anti-viral host response. 437	
Moreover, ECTV encodes two SECRET domain-containing proteins, named E12 and 438	
E184, that show the same chemokine binding specificity16 but these proteins are not 439	
able to compensate for the loss of the CrmD SECRET domain. The phenotype of 440	
ECTVrevSECRET, expressing anti-chemokine activity but lacking TNF/LT inhibitory 441	
activity, indicates that the SECRET domain needs simultaneous TNF blockade to have 442	
a major impact on virus virulence. Additionally, the finding of the SECRET domain on 443	
the same molecule than a TNF binding domain might be relevant to ensure an efficient 444	
combined effect in the infected host. It is reasonable to propose that the coordinated 445	
blockade of cytokines and chemokines by a viral protein could serve as an excellent 446	
inhibitor of cell recruitment and the immune response in vivo, as shown here for the 447	
poxviral CrmD protein and previously for murine cytomegalovirus62.  448	
The study of the contribution of CrmD to mousepox sheds light into the mechanisms of 449	
the pathogenesis of acute viral infections. Importantly, mousepox is a model for human 450	
smallpox, a severe human disease caused by VARV and whose pathogenesis has not 451	
been extensively studied at the molecular level. VARV and ECTV share secreted 452	
immunomodulatory proteins and encode only one vTNFR13,16. The VARV protein 453	
CrmB has TNF/LT and chemokine inhibitory properties similar to those of ECTV 454	
CrmD, but is better adapted to block the human immune system15,16. The control of 455	
TNF-induced gene expression observed in VARV-infected monkeys suggests that 456	
CrmB is expressed during infection63. Our results suggest that VARV CrmB is an 457	
important virulence factor in smallpox. The same may be true for MPXV, an 458	
orthopoxvirus causing a smallpox-like disease in humans with mortality rates of up to 459	
10% that encodes a CrmB orthologue64. The fear of either an intentional release of 460	
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VARV or the emergence of a poxviral zoonosis, caused by MPXV or other 461	
poxviruses25,26 in a large unvaccinated population have sparked the interest in 462	
developing safer vaccines or drugs to prevent or treat human poxviral infections. 463	
Although current vaccines have a proven efficacy record, potential risks relating to 464	
secondary effects, the increased number of immunocompromised individuals and 465	
uncertainty about the duration of protective immunity exist. Thus, alternative strategies 466	
for the development of safer vaccines are being currently pursued (reviewed in65). 467	
Recombinant protein is thought to be safer, and different combinations or single protein 468	
vaccination using components from virus particles, which induce neutralizing 469	
antibodies, protect from poxvirus infections66-68. Our report shows that immunization 470	
with recombinant ECTV CrmD protects mice from a lethal mousepox challenge, 471	
possibly by an antibody-mediated blockade of CrmD-ligand interaction and clearance of 472	
the CrmD protein from the infected host. Similar results have been obtained by 473	
vaccinating with the type I IFN binding protein from ECTV44, and antibodies against 474	
this secreted viral protein protect from mousepox	 69. Thus, secreted poxviral 475	
immunomodulators can act as effective subunit vaccines in preventing a lethal poxvirus 476	
infection in its natural host and could be used singly or in combination with other 477	
proteins. It is important to note that the smallpox VACV vaccines Dryvax and Modified 478	
VACV Ankara do not express the CrmB protein and will not induce a neutralizing 479	
response against CrmB expressed by VARV or MPXV13. However, the Dryvax vaccine 480	
induced an immune response against viral structural proteins that was sufficient to 481	
protect from smallpox. 482	
TNF and chemokines are important in the development of human pathologies unrelated 483	
to viral infection. Notably, soluble TNFRs are used to treat a variety of inflammatory 484	
conditions in the clinic such as rheumathoid arthritis, ankylosing spondylitis or psoriatic 485	
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arthritis70. To date soluble versions of the human TNFR2 or monoclonal anti-TNF 486	
antibodies are used, although other strategies are under development. The use of 487	
vTNFRs in this context has been proposed9,71, and transgenic mice expressing ECTV 488	
CrmD have shown that it can inhibit TNF driven inflammatory reactions in vivo72. The 489	
fact that CrmD acts as a potent anti-inflammatory molecule in vivo and that its SECRET 490	
domain is important for this activity suggests that addition of a chemokine inhibitory 491	
domain to the human soluble TNFRs may increase their clinical efficacy in certain 492	
settings. However, this approach should be taken with caution because an antirheumatic 493	
drug combining anti-TNF and anti-chemokine activities could be expected to further 494	
dampen the already debilitated immune response of patients under anti-TNF therapy, 495	
what might worsen the frequent infectious complications observed in these patients73. 496	
 497	
In conclusion, the characterization of the role of CrmD in mousepox pathogenesis has 498	
demonstrated a critical role of TNF and a specific set of chemokines in defense from 499	
virulent poxvirus infections. The nature of the ligands of CrmD may point to the 500	
cytokines and chemokines important in the control of poxviral infections.  501	
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METHODS 502	
 503	
Cells and viruses 504	
A plaque-purified and fully sequenced ECTV Naval isolate (Naval.Cam) was grown in 505	
BSC-1 cells (ATCC CCL-26)24. For titration of virus in organs from infected mice, 506	
spleen and liver were aseptically removed, weighed and homogeneized and serial 507	
dilutions plated on BSC-1 cell monolayers. For infection of mice, virus stocks were 508	
semipurified by centrifugation through a 36% sucrose cushion74. Viral stocks were 509	
routinely tested for the absence of mycoplasma and the endotoxin levels detected 510	
usingToxiSensor Chromogenic LAL Endotoxin Assay kit (GenScript) were under 0.3 511	
EU/ml. 512	
 513	
Expression and purification of recombinant CrmD proteins 514	
For the generation of anti-CrmD polyclonal rabbit antibodies and immunization 515	
experiments, rabbits and mice, respectively, were injected with a recombinant CrmD 516	
fused to the Fc portion of a human IgG1 (CrmD-Fc). CrmD-Fc was expressed by 517	
recombinant baculoviruses and purified from the supernant of infected Hi5 insect cells 518	
(ThermoFisher BTI-TN-5B1-4) by affinity chromatography in a protein A coupled 519	
sepharose column. Similarly, a CrmD C-terminally tagged with V5 and 6xHis epitopes 520	
was expressed by recombinant baculoviruses as previously described15. A N77F mutant 521	
of this CrmD-V5-6xHis protein was generated using the QuikChange II Site-Directed 522	
mutagenesis kit (Agilent Technologies) and expressed by recombinant baculoviruses15. 523	
 524	
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CrmD anti-TNF activity assay 525	
The ability of ECTV CrmD to block TNF-induced cell death was determined as 526	
described16. Briefly, L929 cells (ATCC CCL-1) were incubated with TNF (R&D 527	
Systems, Minneapolis, USA) which had been preincubated or not with recombinant 528	
ECTV CrmD protein or supernatants from ECTV-infected cells and cell death 529	
determined using the CellTiter OneSolution viability assay (Promega). 530	
 531	
Chemotaxis assays 532	
The anti-chemokine activity of CrmD wild type and the N77F mutant was assessed by 533	
chemotaxis assays using a 96-well ChemoTx plate with a 3-um pore sized filter as 534	
previously described16. Briefly, MOLT-4 cells (ATCC CRL-1582) were incubated with 535	
70 nM of mouse Ccl25 (Peprotech Inc., London, UK) in RPMI 0.1% FBS in the 536	
presence or absence of CrmD wild type or N77F at the indicated molar ratios. 537	
Unspecific migration in the absence of chemokine was also monitored as reference 538	
(media). Cell migration through the filter was allowed to occur during 4 h at 37oC, and 539	
subsequently the number of cells that migrated to the bottom well was calculated by 540	
interpolation in a standard curve of number of cells using CellTiter Aqueous One 541	
Solution assay kit (Promega). 542	
 543	
Surface Plasmon Resonance 544	
The binding affinity of recombinant CrmD for mouse chemokines (Peprotech Inc., 545	
London, UK) and the ability of wild type CrmD and mutant N77F to interact with 546	
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mouse TNF (R&D Systems, Minneapolis, USA) and Ccl25 (Peprotech Inc., London, 547	
UK) were determined by SPR using a Biacore X biosensor (GE Healthcare). 548	
For affinity determinations, recombinant CrmD was immobilized onto a flow cell of a 549	
CM4 chip at low density (900 RUs) by the amine coupling protocol. One flow cell was 550	
left empty to be used as reference. Increasing concentrations of mouse chemokines were 551	
injected in HBS-EP buffer (GE Healthcare) over the chip surface and their binding was 552	
recorded for 120 s followed by a 300 s dissociation period. Surface was regenerated 553	
with glycin-HCl pH2.0 between injections. Binding sensorgrams were analyzed by the 554	
BiaEvaluation software (GE Healthcare) and fitted to a general 1:1 Langmuir binding 555	
model. 556	
For binding assays, recombinant wild type and N77F CrmD proteins were immobilized 557	
on to a flow cell of a CM4 chip at high density (1500 RUs) as explained above. 100 nM 558	
of mouse TNF or mouse Ccl25 were injected over the chip in HBS-EP buffer and their 559	
association was monitored during 120 s followed by a 120 s dissociation. Binding 560	
sensorgrams were processed and analyzed using the BiaEvaluation software. 561	
 562	
Construction of recombinant ECTVs 563	
Recombinant ECTVs were generated using a transient dominant selection procedure 564	
and the selection in the presence of puromycin as previously described74. The plasmid 565	
pMS30 was constructed for expression of EGFP under a VACV early-late promoter 566	
followed by an IRES cassette for expression of the puromycin acetyl transferase gene 567	
from the same transcript. For the generation of ECTVΔCrmD, the flanking regions of 568	
the CrmD gene were PCR-amplified and cloned into the EcoRI and PstI restriction sites 569	
of the polylinker region of pMS30. The 5’ flanking region of the CrmD gene was 570	
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amplified with oligonucleotides CrmD-27 (5’-571	
GCGGAATTCCGATTTAATAACATTCGATTATATAG) and CrmD-11 (5’-572	
CGCGGATCCGGTGTATACGGAACATCTCCAC), and the 3’ flanking region of 573	
CrmD was amplified with oligonucleotides CrmD18 (5’-574	
CGCGGATCCTAACATGGACGTCGTCGCGTATCATAC) and CrmD28 (5’-575	
GCGCTGCAGCTCTGTAATGATGGACGTTATTTC), to generate the plasmid 576	
pMS34 (pΔCrmD). Both flanking regions and the CrmD gene were PCR-amplified with 577	
oligonucleotides CrmD27 and CrmD28 to generate the plasmid pMS37 (pRevCrmD) 578	
that was used for reinsertion of the CrmD gene into the ECTVΔCrmD genome and 579	
construction of ECTVRevCrmD. The 5´flanking region used for generation of ΔcrmD 580	
and the TNF binding domain of CrmD including a stop codon were PCR-amplified 581	
using oligonucleotides CrmD27 and CrmD30 (5´-582	
CGCGGATCCTAACAAGAGGTCTTGTTAACAGGATAC) and pMS37 as a 583	
template. The resulting PCR product was cloned into the EcoRI and BamHI sites of 584	
pMS34 generating plasmid pAH7. This plasmid was used to generate ECTVRevCRD, 585	
which expresses a truncated version of CrmD corresponding to residues M1 to C180. 586	
For the generation of ECTVRevSECRET, the CrmD gene contained in pMS37 was 587	
mutated by directed single point mutation using the QuickChange II mutagenesis kit 588	
(Agilent Technologies) and the primers CrmD43 589	
(AGATGACACCTTTACATCCATTCCTTTTCATAGTCCCGCGTG) and CrmD44 590	
(CACGCGGGACTATGAAAAGGAATGGATGTAAAGGTGTCATCT). These 591	
primers introduce a N77F mutation in CrmD. 592	
After transfection/infection in BSC-1 cells, the intermediate single-crossover 593	
recombinant viruses in which the complete plasmid has been inserted into the ECTV 594	
genome were selected for three to five consecutive infection rounds in the presence of 595	
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puromycin and monitored for EGFP expression by fluorescence microscopy. 596	
Recombinant viruses (ECTVΔCrmD, ECTVRevCrmD, ECTVRevCRD and 597	
ECTVRevSECRET) were finally selected by successive plaque purification of white 598	
plaques in the absence of puromycin and screening with a CrmD-specific PCR. The 599	
complete genome sequence of ECTVRevCRD and ECTVRevSECRET was determined 600	
by Illumina sequencing to confirm the genomic structure and the absence of inadvertent 601	
mutations that may affect virus virulence24. The sequences have been submited to the 602	
European Nucleotide Archive and have been assigned reference number PRJEB19928. 603	
The number of sequencing reads that aligned with the ECTV Naval genome was 1,29 x 604	
106 (93% of total sequencing reads) for ECTVRevCRD and 1,27 x 106 (87,4% of total 605	
sequencing reads) for ECTVRevSECRET. ECTVRevCRD was sequenced with a 325x 606	
coverage and, including the expected introduction of a truncated version of the 607	
duplicated CrmD gene, three changes were identified: D5.655-5.998 (EVN006/CrmD 608	
gene); T199.552C (EVN200P pseudogene) and D201.621-201.964 (EVN201/CrmD 609	
gene). ECTVRevSECRET was sequenced with a 320x coverage and, including the 610	
expected N77F mutation in the amino acid sequence of duplicated CrmD gene, three 611	
changes were identified: TT6.310-6.311AA (EVN006/CrmD gene); T199.552C 612	
(EVN200P pseudogene) and AA201.310-201.311TT (EVN201/CrmD gene). Both 613	
recombinant viruses had the expected mutations in both copies of the CrmD gene, 614	
present at the left and right ends of the viral genome. We also identified an additional 615	
point mutation in the inactive pseudogene EVN200P that was present in both 616	
ECTVRevCRD and ECTVRevSECRET, suggesting that this mutation was introduced 617	
during the generation of ECTVΔCrmD. 618	
 619	
Infection of mice 620	
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Female BALB/c OlaHsd mice (6-8 weeks old) (Harlan), housed in ventilated racks, 621	
were anesthesized with isofluorane and s.c. infected in the footpad with 10 µl of virus 622	
inoculum. Viral doses were confirmed by titrating again on the same day the virus 623	
dilutions used for mouse infections. Mice were housed in ventilated racks (Tecniplast) 624	
under biological safety level 3 containment facilities. Monitoring of infected animals 625	
was performed daily. Animals were weighed, scored for clinical signs of illness (scores 626	
ranging from 0 for healthy animals to 4 for severely diseased animals) and footpad 627	
swelling measured. Data analysis was performed using GraphPad Prism 6 (GraphPad 628	
Software, La Jolla, CA, USA). Survival curves were compared using the Logrank 629	
(Mantel-Cox) test. Footpad swelling and % initial weight data were analysed using 630	
multiple t tests with false discovery rate Q=1%. Analyses were performed up to times 631	
post-infection at which survival rates in the corresponding groups were above 50%. 632	
ANOVA analyses with Bonferroni multiple comparison tests were performed in some 633	
experiments, as indicated, for comparisons among groups and times post-infection at 634	
which no mortalities were observed. These experiments were approved by the 635	
Biological Safety Committee of the Centro de Investigación en Sanidad Animal (CISA, 636	
INIA, Valdeolmos, Madrid) and animals were housed and handled according to legal 637	
requirements. 638	
 639	
Immunohistochemistry and semiquantitative analyses 640	
Footpad, spleen and liver samples from infected mice were removed aseptically and 641	
fixed in 10% buffered formalin solution to detect virus, ECTV CrmD protein and 642	
chemokine receptors, and in zinc fixative (BDPharmingen) to detect lymphoid cells and 643	
ICAM-1. After fixation, the samples were dehydrated through a graded series of alcohol 644	
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to xylol and embedded in paraffin wax. For structural and immunohistochemical 645	
analysis, sections (3 µm) were cut and stained with H&E or processed for 646	
immunohistochemical techniques. To detect virus and ECTV CrmD protein, formalin 647	
fixed serial sections were incubated with polyclonal rabbit anti-VACV antibody from a 648	
VACV-infected rabbit or a polyclonal rabbit anti-CrmD antibody against purified CrmD 649	
expressed in the baculovirus system. Both antibodies were generated in our laboratory. 650	
Secondary goat anti-rabbit IgG (Dako) was detected using an avidin-peroxidase-651	
complex kit (PIERCE, Thermo Scientific) and 3,3´-diaminobenzidine 652	
tetrahydrochloride (Sigma) following the manufacturer´s instructions. The slides where 653	
counterstained with Mayer´s haematoxylin, dehydrated, and mounted with DPX 654	
mountant (Surgipath). Specific primary antibodies were replaced by PBS or normal goat 655	
serum in negative control sections. To detect lymphoid cells and chemokine receptors, 656	
the avidin-biotin alkaline-phosphatase staining method was used. Sections were 657	
dewaxed and immunostained with polyclonal rabbit anti-human CD3 (Dako), rat anti-658	
mouse CD45R/B220, CD4, CD8a, and CD8b (BD Pharmingen) or goat anti-mouse 659	
CCR10 (AbCAM). Anti-mouse ICAM-1 antibody was from AbCAM. For CD3 and 660	
CCR10 immunohistochemistry, antigen retrieval was achieved by heating sections in 661	
0.1 M citrate buffer at pH 6. Secondary goat anti-rabbit IgG, rabbit anti-rat IgG, or 662	
rabbit anti-goat IgG (Dako) were used as corresponded with the streptavidin-biotin-663	
alkaline phosphatase kit (PIERCE, Thermo Scientific) and “FastRed” (Fast red sustrate 664	
packs, Lab Biogenex®) for detection of the immunogens, following the manufacturer’s 665	
indications. The slides were counterstained with Mayer’s haematoxylin, and mounted 666	
with Immu-mount (Thermo Shandon). Specific primary antibodies were replaced by 667	
PBS, normal rabbit serum or normal goat serum in negative control sections. 668	
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For semi-quantitative analyses of histological sections, samples from at least 5 animals 669	
for each parameter were analysed in every case. To establish the degree of necrosis, a 670	
minimum of 10 fields were scored per spleen and liver slice to obtain the mean value. 671	
To quantify the morphological changes, sections were graded for necrosis using an 672	
arbitrary scale: - negative findings (0 %); + slight (about 25 % necrosis); ++ moderate 673	
(about 50 % necrosis); +++ very intense (about 90-100 % necrosis). Inflammatory 674	
infiltration was evaluated in a minimum of 10 fields per liver slice or the complete 675	
footpad section to obtain the mean value and it was scored as: - negative findings; + 676	
slight; ++ moderate; +++ very intense. For antibody staining of lymphoid cells and 677	
CCR10 chemokine receptor expressing cells, all the cells from the inflammatory 678	
infiltrate were counted for each case and mean values are presented. In the case of anti-679	
ICAM-1 staining, all the blood vessels from sections from ECTV- (n = 5), 680	
ECTVRevCrmD- (n = 5), and ECTVΔCrmD- (n = 6) infected mice were analysed and 681	
scored as staining or non-staining. Mean percentage of staining vessels and standard 682	
deviations were calculated using the Excel spreadsheet and statistical significance was 683	
confirmed using a Student´s t-test (p < 0.01). 684	
 685	
Flow cytometry 686	
DPLN and spleens from PBS-inoculated or ECTV-infected BALB/c mice were 687	
collected at 2 and 7 dpi, respectively, in RPMI supplemented with 10% FCS. Cell 688	
suspensions were obtained by homogenization of the organs through 40 µm cell 689	
strainers (BD Bioscience). Red blood cells were lysed by hypoosmotic shock in milli-Q 690	
water and white cells were washed twice in PBS and counted manually in a 691	
haemocytometer. DPLN cells were stained with anti-DX5-FITC (eBioscience), anti-692	
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CD3e-PerCP (eBioscience) and anti-GzB-APC (R&D Biosystems). Splenocytes were 693	
stained with anti-CD3e-PerCP, anti-CD8-PE (eBioscience) and anti-GzB-APC. In 694	
parallel, cell suspensions were also stained with the appropriate isotype control 695	
antibodies. 100,000 cells were analyzed in a FACS Calibur flow cytometer (Becton 696	
Dickinson). Events were gated according to a forward and side scatter pattern 697	
compatible with healthy lymphocytes (Supplementary Fig. 3). Results were analysed 698	
with FlowJo software (FlowJo LLC). 699	
 700	
Immunization with recombinant purified ECTV CrmD 701	
A group of 15 female (6-8 week old) BALB/c mice was inoculated i.p. with 10 µg of 702	
purified recombinant ECTV CrmD protein expressed in the baculovirus system per 703	
animal three times at 17 to 20 d intervals. At 18 d after the last inoculation, mice were 704	
bled and sera obtained to check for presence of anti-CrmD antibodies and challenged 705	
s.c. with 1,000 PFU of ECTV as above. As a control, a group of 10 BALB/c mice was 706	
subjected to the same protocol using PBS for i.p. inoculations and infected with equal 707	
amounts of virus. Disease progression was monitored as described above. 708	
 709	
Data availability 710	
The data that support the findings of this study are available from the corresponding 711	
author upon reasonable request. The viral genomic sequences reported have been 712	
submited to the European Nucleotide Archive and have been assigned reference number 713	
PRJEB19928 (www.ebi.ac.uk/ena/data/view/PRJEB19928). 714	
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LEGENDS TO FIGURES 985	
 986	
Figure 1. ECTV CrmD recombinant viruses 987	
(a) Schematic diagram of the genomic structure of the recombinant ECTVs generated 988	
for the study of the role of ECTV CrmD in mousepox pathogenesis. The names of the 989	
genes flanking the CrmD locus are indicated. In grey, the CrmD locus in the parental 990	
and recombinant viruses is shown. Both left Inverted Terminal Repeat (lITR) and right 991	
ITR (rITR) are represented for ECTV, whereas the lITR is shown for the other viruses. 992	
(b) Western blot analyses using anti-CrmD and anti-35-kDa vCKBP antisera of 993	
supernatants from BSC-1 cells that were mock-infected (1) or infected with ECTV (2), 994	
ECTVΔCrmD (3), ECTVRevCrmD (4) or ECTVRevCRD (5) at a multiplicity of 995	
infection of 5 PFU/cell and harvested at 24 h post-infection. The position of the 996	
respective proteins is indicated by arrows. Molecular size markers in kDa are shown on 997	
the left. (c) TNF-induced cytotoxicity assay. Increasing amounts of recombinant ECTV 998	
CrmD (rCrmD, in µg/ml) or supernatants (equivalent to 5, 10 or 30 x 103 cells) obtained 999	
as in panel B were added to block the effect of TNF on L929 cells. The values obtained 1000	
in the presence of mock-infected cell supernatants have been substracted in each case. 1001	
Data are mean + / - standard error of the mean (SEM) of triplicate samples. (d) Single-1002	
step growth curves of the indicated viruses. BSC-1 cells were infected with 5 PFU/cell 1003	
and the virus production was titrated at the indicated h post-infection. The means of 1004	
duplicate samples are shown. 1005	
 1006	
 1007	
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Figure 2. Mousepox pathogenesis in the absence of ECTV CrmD 1008	
Groups of 10 (left panels) or 5 (right panels) BALB/c mice were inoculated s.c. in the 1009	
left hind footpad with 10 PFU or 1,000 PFU, respectively, of ECTV (¡), ECTVΔCrmD 1010	
(p), ECTVRevCrmD (l), ECTVRevCRD (r) or PBS alone (n ), and monitored daily 1011	
for weight loss, signs of illness and footpad swelling, as indicated. Data are shown as 1012	
mean + / - SEM. Statistical analyses were performed using multiple t-tests with false 1013	
discovery rate at Q=1%. Analyses were performed up to times post infection at which 1014	
survival rates in the corresponding group were above 50%. Black bars indicate time 1015	
points at which significant differences (p < 0.01) between ECTV- / ECTVRevCrmD- 1016	
and ECTVΔCrmD-inoculated mice were found. Asterisks indicate time points at which 1017	
significant differences (p < 0.01) between ECTVΔCrmD and ECTVRevCRD-1018	
inoculated mice were found. The bottom panels show the number of surviving animals 1019	
during the course of infection. Data are from one experiment representative of three 1020	
independent experiments. 1021	
 1022	
Figure 3. Inflammatory response in the footpad of ECTVΔCrmD-infected mice 1023	
Left hind foot (a, b) and H&E staining (c, d) and anti-ICAM-1 staining (e, f) of zinc-1024	
fixed footpad sections of representative BALB/c mice infected with 1,000 PFU of 1025	
ECTV (a, c, e) or ECTVΔCrmD (b, d, f) at 7 dpi. Anti-CD4 staining (g) of zinc-fixed 1026	
and anti-CCR10 staining (h) of formalin-fixed footpad sections of representative 1027	
ECTVΔCrmD-infected mice are shown. No cell infiltrate was observed in the ECTV-1028	
infected tissues. For all immunohistochemistry analyses, postively labelled cells appear 1029	
in red colour. Scale bar, 100 µm (c-f) and 25 µm (g, h). 1030	
 1031
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Figure 4. CrmD binding affinity for mouse chemokines. (a) Binding screening of 1032	
mouse chemokines to CrmD. Recombinant CrmD was immobilizedon a CM4 SPR 1033	
biosensor chip at 1500 RU. Chemokines (100 nM) were injected at 10 µl/min flow rate 1034	
in HBS-EP buffer. Binding was monitored during 180 s followed by a 120 s 1035	
dissociation periods. (b) Binding kinetic constants -Ka (association), Kd (dissociation) 1036	
and KD (affinity)- and their corresponding SEM for the CrmD interaction with some of 1037	
its chemokine ligands. For affinity determination purposes, CrmD was immobilized on 1038	
a CM4 SPR biosensor chip at 900 RUs. The bindingof increasing concentrations of 1039	
chemokine (1-50 nM), injected at a 30 µl/min flow rate, was recorded during 120 s 1040	
followed by a 300 s dissociation. Binding curves were fitted according to a 1:1 1041	
Langmuir model. (c) Two examples of affinity determination fittings are shown. 1042	
 1043	
Figure 5. Impaired virus spread in the absence of ECTV CrmD 1044	
Graphs show viral titres at 3, 7 and 11 dpi in spleen (a) and liver (b) of BALB/c mice 1045	
infected with 1,000 PFU per animal of the indicated viruses. Data are mean log +/- 1046	
SEM of groups of 5 animals for each condition. Note that mice infected with ECTV or 1047	
ECTVRevCrmD did not survive to 11 dpi. Left hind foot anti-poxvirus staining (c-e) or 1048	
anti-CrmD staining (f-h) of zinc-fixed footpad sections of representative BALB/c mice 1049	
infected with 1,000 PFU of ECTVRevCrmD (c, f), ECTVΔCrmD (d, g) or 1050	
ECTVRevCRD (e, h) at 7 dpi. H&E staining of spleen (i-k) or liver (l-n) sections of 1051	
representative mice infected with 1,000 PFU of ECTVRevCrmD (i, l), ECTVΔCrmD (j, 1052	
m) or ECTVRevCRD (k, n) at 7 dpi. Insets show enlargement of selected areas to 1053	
illustrate necrosis (l, n) and inflammatory infiltrate (m). Data are from one experiment 1054	
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representative of two independent experiments. Scale bar, 100 µm (c-k) and 40 µm (l-1055	
n). 1056	
 1057	
Figure 6. CrmD N77F mutant blocks chemokines but lacks anti-TNF activity  1058	
(a) Coomasie blue stained gel showing 500 ng of recombinant CrmD wild type (WT) 1059	
and N77F mutant expressed by recombinant baculoviruses.Molecular mass standards 1060	
are shown in kDa. (b) CrmD N77F binds mouse Ccl25 but not mouse TNF (mTNF). 1061	
The binding of 100 nM Ccl25 andmTNF to CrmD WT or N77F mutant was assessed 1062	
by SPR experiments. (c) CrmD N77F mutant does not interfere with mouse TNF-1063	
mediated cytotoxicity on L929 cells. The cell viability of L929 cells after a 18 h 1064	
incubation with 1.2 nM TNF in the absence or presenceof the indicated molar ratios of 1065	
CrmD variants was determined. Data is represented as mean ± standard deviation (SD) 1066	
of the % relative to cells incubated without TNF (media). (d) CrmD N77F blocks mouse 1067	
Ccl25-induced migration of MOLT-4 cells. The number of cells that migrated through 1068	
the transwell filter after 4 h incubation at 37oC with 50 nM mouse Ccl25 in the absence 1069	
or presence of the indicated increasing molar ratios of CrmD variants is shown. Data is 1070	
represented as mean ± SD of triplicates. In c and d, one experiment representative of 1071	
three independent experiments is shown. 1072	
 1073	
Figure 7. The activity of the SECRET domain in vivo is dependent on concomitant 1074	
TNF blockade 1075	
(a) Schematic diagram of the genomic structure of ECTV RevSECRET. The genes 1076	
flanking the CrmD locus are indicated. In grey, the CrmD locus in the parental and 1077	
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recombinant virus is shown. Presence of a point mutation (N77F) in the CrmD of 1078	
ECTVRevSECRET is indicated by an asterisk and a black line. Only the left Inverted 1079	
Terminal Repeat is shown. (b) Western blot analyses using anti-CrmD and anti-35-kDa 1080	
vCKBP antisera of supernatants from BSC-1 cells mock-infected (1) or infected with 1081	
ECTVΔCrmD (2), ECTVRevCrmD (3), ECTVRevCRD (4) or ECTVRevSECRET (5) 1082	
at a multiplicity of infection of 5 PFU/cell and harvested at 24 h post-infection. The 1083	
position of the proteins is indicated by arrows. Molecular size markers in kDa are 1084	
shown on the left. (c) TNF-induced cytotoxicity assay. Increasing amounts of 1085	
supernatants (equivalent to 2, 8 or 16 x 103 cells) from cells infected with the indicated 1086	
viruses were added to block the effect of TNF on L929 cells. Values of % cell viability 1087	
obtained in the presence of mock-infected cell supernatants were subtracted from the % 1088	
cell viability caused by the corresponding supernatant volume from virus-infected cells. 1089	
Data are mean +/- SD of triplicate samples. (d) Mortality rate determination of CrmD 1090	
recombinant ECTVs in susceptible mice. Groups of 5 or 10 female BALB/c mice were 1091	
infected s.c. in the left hind footpad with different doses of the indicated viruses. The 1092	
number of survivors at 15 dpi and the mean time to death (MTD) in days for each 1093	
condition are shown. n.a., not applicable. (e) Groups of 5 female BALB/c mice were 1094	
inoculated s.c. in the left hind footpad with 106 PFU of ECTV RevCrmD (l), 1095	
ECTVΔCrmD (p), ECTVRevCRD (r) or ECTVRevSECRET (¨) and monitored 1096	
daily for mortality and footpad swelling, as indicated. Data are shown as mean +/- SD. 1097	
Asterisks indicate time points at which significant differences (p < 0.01, multiple t tests 1098	
with false discovery rate correction at Q=1%) between ECTVΔCrmD and 1099	
ECTVRevSECRET-inoculated mice were found. (f) Replication of recombinant ECTVs 1100	
in spleen. Viral titres at 7 dpi in spleen of mice infected with 105 PFU per animal of the 1101	
indicated viruses. Data are mean log +/- SD of groups of 5 mice for each condition. 1102	
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Groups significantly different from the ECTVRevCrmD-infected group are indicated 1103	
(asterisks p<0.05, ANOVA with Bonferroni multiple comparison test).  1104	
 1105	
Figure 8. Inhibition of TNF activity in vivo impairs NK cell activation in response 1106	
to ECTV infection 1107	
Cells from DPLN (a, b, c, d) harvested at 2 dpi or from spleens (a, e, f) collected at 7 1108	
dpi from PBS-inoculated BALB/c mice or mice infected with 105 pfu of the indicated 1109	
viruses were analyzed by flow cytometry using conjugated anti-CD3, anti-CD8, anti-1110	
DX5 and anti-granzyme B (GzB) antibodies. In A, representative dot plots of the 1111	
staining of NK cells (CD3- DX5+; top panel) and CD8 T cells (CD3+ CD8+; bottom 1112	
panel) isolated from DPLN or spleen, respectively, are shown. Number inside each 1113	
graph indicates the % of cells inside the depicted gates. In b and c, a quantification of 1114	
the total number and % of NK cells, respectively, is presented. The % of NK cells 1115	
expressing granzyme B in each group is quantified in d. In e and f, a quantification of 1116	
the total number of CD8 T cells and granzyme B-expressing CD8 T cells detected for 1117	
each group is shown. The number of events positively stained with the corresponding 1118	
isotype control antibodies (isotype DX5, 0.15% positives; isotype CD8, 1.3% positives; 1119	
isotype granzyme B, 0.02% and 0.03% positives in DPLN and spleen, respectively) 1120	
were subtracted from each sample for the quantification analyses. Data are mean +/- SD 1121	
from one experiment representative of three independent experiments with 4-5 animals 1122	
per group. Statistically significant groups are indicated (asterisks p<0.05, ANOVA with 1123	
Bonferroni multiple comparison test). 1124	
 1125	
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Figure 9. Immunization with purified recombinant ECTV CrmD protects mice 1126	
from fatal mousepox 1127	
Groups of BALB/c mice were immunized with PBS (n = 10) (PBS, open circle) or 1128	
recombinant ECTVCrmD protein (n = 15) (rCrmD, close triangle), and challenged with 1129	
1,000 PFU of ECTV per animal at 18 d after concluding the immunization procedure. 1130	
(a) Neutralization of TNF activity in a TNF-induced cytotoxicity assay by serum from 1131	
mice immunized with CrmD or PBS. L929 cells were incubated with TNF and CrmD in 1132	
the presence of 1 µl (open bars) or 2 µl (close bars) of serum from mice immunized 1133	
with CrmD (CrmD 1-15) or PBS (PBS 1-2). As controls, cell viability was determined 1134	
in the absence of TNF (no TNF) or in the presence of TNF (TNF) incubated also with 1135	
CrmD (TNF CrmD) or an antiserum against CrmD (anti CrmD). Mice that succumbed 1136	
to infection are indicated with a cross. Data are mean +/- SEM of triplicate samples. 1137	
Mice infected with ECTV were monitored for weight loss (b), signs of illness (c), 1138	
footpad swelling (d) and mortality (e) at the indicated times of infecion. Data are shown 1139	
as mean +/- SEM. 1140	
 1141	
 1142	
 1143	
  1144	
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Table	 1:	 Mortality	 rate	 determination	 of	 CrmD	 recombinant	 ECTVs	 in	1145	
susceptible	BALB/c	mice		1146	
Dose	(pfu)	 ECTV	 ECTV	RevCrmD	 ECTV	∆CrmD	 ECTV	RevCRD	survivors	 MTD	 survivors	 MTD	 survivors	 MTD	 survivors	 MTD	
10	 4/10	 10.0	(9-11)	 0/10	 11.6	(9-21)	 10/10	 n.a.	 10/10	 n.a.	
10e2	 0/5	 11.8	(9-18)	 1/5	 12.8	(10-11)	 5/5	 n.a.	 5/5	 n.a.	
10e3	 0/5	 10.4	(9-14)	 0/5	 10.2	(9-13)	 5/5	 n.a.	 4/5	 10	
10e4	 n.d.	 n.d.	 0/5	 8.6	(8-10)	 5/5	 n.a.	 5/5	 n.a.	
10e5	 n.d.	 n.d.	 0/5	 9.6	(8-13)	 5/5	 n.a.	 3/5	 9	(8-10)	
10e6	
10e7	
n.d.	
n.d.	
n.d.	
n.d.	
n.d.	
n.d.	
n.d.	
n.d.	
5/5	
4/5	
n.a.	
14	
n.d.	
1/5	
n.d.	
12.5	(10-16)	
	1147	
Groups	of	5	or	10	BALB/c	 female	mice	were	 infected	s.c.	 in	 the	 left	hind	 footpad	1148	 with	different	 doses	of	 the	 indicated	 viruses.	The	 number	 of	 survivors	 at	 32	 dpi	1149	 and	 the	mean	 time	 to	 death	 (MTD)	 and	 survival	 range	 (in	 parenthesis)	 in	 d	 for	1150	 each	condition	are	shown.	n.a.,	not	applicable;	n.d.,	not	determined.	1151	
  1152	
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Table	 2:	 Histopathology	 of	 spleen	 and	 liver	 in	 recombinant	 ECTV-infected	1153	
mice		1154	
	 3	dpi	 7	dpi	 11	dpi	
	 spleena	 livera	/	b	 spleena	 livera	/	b	 spleena	 livera	/	b	
EV	 -	 -	/	-	 +++	 +	/	+	 n.a.	 n.a.	
EV	RevCrmD	 -	 -	/	-	 +++	 +	/	+	 n.a.	 n.a.	
EV	∆CrmD	 -	 -	/	-	 +	 -	/	++	 +	 -	/	++	
EV	RevCRD	 -	 -	/	-	 ++	 +	/	+	 +	 -	/	++	
	1155	
	1156	
Groups of 5 BALB/c mice were infected s.c. in the left hind footpad with the indicated 1157	
viruses and sacrificed at different dpi. Spleen and liver were H&E-stained for 1158	
histopathological analysis. Degree of necrosisa was semiquantitatively assessed using an 1159	
arbitrary scale: - negative findings (0 %); + slight (about 25 % necrosis); ++ moderate 1160	
(about 50 % necrosis); +++ very intense (about 90-100 % necrosis). Presence of 1161	
inflammatory infiltrateb was evaluated in a minimum of 10 fields per liver slice section 1162	
to obtain the mean value and it was scored as: - negative findings; + slight; ++ 1163	
moderate; +++ very intense. n.a. not applicable. 1164	
 1165	
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